Literature DB >> 7816213

Ontogeny of D1A and D2 dopamine receptor subtypes in rat brain using in situ hybridization and receptor binding.

U B Schambra1, G E Duncan, G R Breese, M G Fornaretto, M G Caron, R T Fremeau.   

Abstract

The prenatal and postnatal ontogeny of D1A and D2 dopamine receptors was assessed by in situ hybridization of messenger RNAs encoding the receptors and by radioligand binding autoradiography. On gestational day 14, signals for D1A and D2 dopamine receptor messages were observed in selected regions in ventricular and subventricular zones which contain dividing neuroblasts, and in intermediate zones that contain maturing and migrating neurons. Specifically, D1A and D2 dopamine receptor message was observed in the developing caudate-putamen, olfactory tubercle, and frontal, cingulate, parietal and insular cortices. Additionally, D1A dopamine receptor messenger RNA was found in the developing epithalamus, thalamus, hypothalamus, pons, spinal cord and neural retina; D2 dopamine receptor messenger RNA was also observed in the mesencephalic dopaminergic nuclear complex. Gene expression of D1A and D2 dopamine receptor subtypes in specific cells as they differentiate precedes dopamine innervation and implies that receptor expression is an intrinsic property of these neurons. The early expression of dopamine receptor messenger RNA suggests a regulatory role for these receptors in brain development. While the signal for both messages increased in the intermediate zones on gestational day 16, it decreased in the ventricular and subventricular zones, and was no longer apparent in these zones by gestational day 18. By gestational day 18, abundant D1A or D2 dopamine receptor messenger RNA was observed in cell groups similar in location to those observed in the adult brain. On gestational day 18, D1A dopamine receptor message was noted in the neural retina, anterior olfactory nucleus, the insular, prefrontal, frontal, cingulate, parietal and retrosplenial cortices, the olfactory tubercle, caudate-putamen, lateral habenula, dorsolateral geniculate nucleus, ventrolateral and mediolateral thalamic nuclei, and the suprachiasmatic and ventromedial nuclei of the hypothalamus. D2 dopamine receptor message was observed on gestational day 18 in the insular, prefrontal, frontal and cingulate cortices, the olfactory tubercle, caudate-putamen, ventral tegmental area, substantia nigra, and the intermediate lobe of the pituitary. At birth, expression of messenger RNA for both dopamine receptor subtypes in the striatum approximated that seen in mature rats. In contrast, D1A and D2 receptor binding, measured with [3H]SCH-23390 and [3H]raclopride, respectively, was low at birth and progressively increased to reach adult levels between days 14 and 21. The in situ hybridization data showing early prenatal expression of messenger RNA for the D1A and D2 dopamine receptors are consistent with the hypothesis that these receptors have a regulatory role in neuronal development.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7816213     DOI: 10.1016/0306-4522(94)90315-8

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  38 in total

1.  Neuron specific alpha-adrenergic receptor expression in human cerebellum: implications for emerging cerebellar roles in neurologic disease.

Authors:  U B Schambra; G B Mackensen; M Stafford-Smith; D E Haines; D A Schwinn
Journal:  Neuroscience       Date:  2005       Impact factor: 3.590

2.  Altered dendritic distribution of dopamine D2 receptors and reduction in mitochondrial number in parvalbumin-containing interneurons in the medial prefrontal cortex of cannabinoid-1 (CB1) receptor knockout mice.

Authors:  Megan L Fitzgerald; June Chan; Kenneth Mackie; Carl R Lupica; Virginia M Pickel
Journal:  J Comp Neurol       Date:  2012-12-01       Impact factor: 3.215

3.  The partial D2-like dopamine receptor agonist terguride acts as a functional antagonist in states of high and low dopaminergic tone: evidence from preweanling rats.

Authors:  Sanders A McDougall; Rita M Hernandez; Carmela M Reichel; Cristal M Farley
Journal:  Psychopharmacology (Berl)       Date:  2004-11-18       Impact factor: 4.530

4.  Dopamine promotes the survival of embryonic striatal cells: involvement of superoxide and endogenous NADPH oxidase.

Authors:  Liping Ma; Jiawei Zhou
Journal:  Neurochem Res       Date:  2006-05-09       Impact factor: 3.996

5.  Expression and distribution of all dopamine receptor subtypes (D(1)-D(5)) in the mouse lumbar spinal cord: a real-time polymerase chain reaction and non-autoradiographic in situ hybridization study.

Authors:  H Zhu; S Clemens; M Sawchuk; S Hochman
Journal:  Neuroscience       Date:  2007-09-12       Impact factor: 3.590

Review 6.  Drugs, biogenic amine targets and the developing brain.

Authors:  Aliya L Frederick; Gregg D Stanwood
Journal:  Dev Neurosci       Date:  2009-04-17       Impact factor: 2.984

7.  Expression and function of dopamine receptors in the developing medial frontal cortex and striatum of the rat.

Authors:  S E Sillivan; C Konradi
Journal:  Neuroscience       Date:  2011-10-08       Impact factor: 3.590

Review 8.  Neurobehavioral evidence for changes in dopamine system activity during adolescence.

Authors:  Dustin Wahlstrom; Tonya White; Monica Luciana
Journal:  Neurosci Biobehav Rev       Date:  2009-12-21       Impact factor: 8.989

9.  Targeted expression of a toxin gene to D1 dopamine receptor neurons by cre-mediated site-specific recombination.

Authors:  J Drago; P Padungchaichot; J Y Wong; A J Lawrence; J F McManus; S H Sumarsono; A L Natoli; M Lakso; N Wreford; H Westphal; I Kola; D I Finkelstein
Journal:  J Neurosci       Date:  1998-12-01       Impact factor: 6.167

10.  Elevated dopamine levels during gestation produce region-specific decreases in neurogenesis and subtle deficits in neuronal numbers.

Authors:  Deirdre McCarthy; Paula Lueras; Pradeep G Bhide
Journal:  Brain Res       Date:  2007-09-21       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.